Your browser is no longer supported. Please, upgrade your browser.
Settings
ARQT Arcutis Biotherapeutics, Inc. daily Stock Chart
ARQT [NASD]
Arcutis Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-3.45 Insider Own2.50% Shs Outstand37.75M Perf Week21.27%
Market Cap1.12B Forward P/E- EPS next Y-4.01 Insider Trans- Shs Float20.56M Perf Month28.86%
Income-114.20M PEG- EPS next Q-0.85 Inst Own79.80% Short Float6.00% Perf Quarter5.45%
Sales- P/S- EPS this Y-118.10% Inst Trans2.93% Short Ratio5.37 Perf Half Y-23.68%
Book/sh4.58 P/B5.66 EPS next Y-2.60% ROA-57.70% Target Price- Perf Year-
Cash/sh4.40 P/C5.89 EPS next 5Y9.80% ROE-81.70% 52W Range17.10 - 40.88 Perf YTD18.99%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.55% Beta-
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low51.70% ATR1.39
Employees29 Current Ratio9.20 Sales Q/Q- Oper. Margin- RSI (14)66.28 Volatility6.13% 6.91%
OptionableNo Debt/Eq0.00 EPS Q/Q-156.00% Profit Margin- Rel Volume0.21 Prev Close25.62
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume229.77K Price25.94
Recom1.80 SMA2023.81% SMA5012.27% SMA200-2.50% Volume48,571 Change1.25%
Nov-09-20Upgrade Goldman Neutral → Buy $34 → $36
Oct-08-20Initiated Truist Buy $38
Feb-25-20Initiated Guggenheim Buy $36
Feb-25-20Initiated Goldman Neutral $30
Feb-25-20Initiated Cowen Outperform $55
Feb-25-20Initiated Cantor Fitzgerald Overweight $50
Nov-27-20 11:55AM  
Nov-23-20 07:30AM  
Nov-11-20 04:05PM  
Nov-05-20 04:05PM  
Nov-04-20 04:05PM  
Nov-02-20 09:00AM  
Oct-29-20 09:07PM  
Oct-26-20 09:00AM  
Oct-08-20 10:00AM  
Oct-06-20 04:05PM  
Oct-02-20 12:40PM  
Oct-01-20 10:47PM  
Sep-29-20 04:51PM  
02:36PM  
08:00AM  
Sep-16-20 09:00AM  
Sep-15-20 09:00AM  
Sep-08-20 09:00AM  
Aug-11-20 04:02PM  
Aug-10-20 09:00AM  
Aug-04-20 09:00AM  
Aug-03-20 09:00AM  
Jul-31-20 09:00AM  
Jul-27-20 09:00AM  
Jul-20-20 09:00AM  
Jul-15-20 05:07PM  
Jul-13-20 09:00AM  
Jun-22-20 11:47AM  
09:00AM  
Jun-10-20 04:05PM  
Jun-01-20 09:00AM  
May-27-20 09:00AM  
May-12-20 04:05PM  
Apr-27-20 08:30AM  
Apr-21-20 09:00AM  
Mar-23-20 08:30AM  
Mar-16-20 08:37AM  
Mar-05-20 08:30AM  
Mar-03-20 08:30AM  
Feb-19-20 08:30AM  
Feb-14-20 08:00PM  
Feb-13-20 08:30AM  
Feb-04-20 04:05PM  
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Welgus Howard G.DirectorNov 12Option Exercise0.581,222709179,844Nov 13 11:57 AM
Welgus Howard G.DirectorNov 02Option Exercise1.682,2003,696180,822Nov 04 04:33 PM
Welgus Howard G.DirectorNov 02Sale18.272,20040,186178,622Nov 04 04:33 PM
Lock Kenneth A.Chief Commercial OfficerOct 26Option Exercise6.522,66817,39521,863Oct 27 02:03 PM
Lock Kenneth A.Chief Commercial OfficerOct 22Option Exercise6.522,69517,57119,195Oct 23 01:27 PM
Lock Kenneth A.Chief Commercial OfficerOct 15Option Exercise6.527,50048,90016,500Oct 16 02:06 PM
Welgus Howard G.DirectorOct 15Option Exercise0.581,222709178,622Oct 16 02:06 PM
ORBIMED ADVISORS LLCDirectorOct 02Buy25.00496,00012,400,0004,267,564Oct 06 05:27 PM
SILVERSTEIN JONATHANDirectorOct 02Buy25.00496,00012,400,0004,267,564Oct 06 05:23 PM
Welgus Howard G.DirectorOct 01Option Exercise1.682,2003,696179,210Oct 05 09:13 PM
Welgus Howard G.DirectorOct 01Sale27.652,20060,829177,400Oct 05 09:13 PM
Smither John WChief Financial OfficerSep 29Option Exercise1.6850084024,375Oct 01 09:00 PM
Watanabe Todd FranklinPresident and CEOSep 29Option Exercise1.683,0005,042569,928Oct 01 09:02 PM
Watanabe Todd FranklinPresident and CEOSep 29Sale30.003,00090,000566,928Oct 01 09:02 PM
Smither John WChief Financial OfficerSep 29Sale30.001,25037,50098,715Oct 01 09:00 PM
Smither John WChief Financial OfficerSep 29Sale30.0050015,00023,875Oct 01 09:00 PM
OSBORNE DAVID WChief Technical OfficerSep 29Sale30.0015,000450,000264,279Oct 01 09:01 PM
Welgus Howard G.DirectorSep 15Option Exercise0.581,222709177,400Sep 16 05:57 PM
Welgus Howard G.DirectorSep 01Option Exercise1.682,2003,696178,378Sep 02 11:48 AM
Welgus Howard G.DirectorSep 01Sale24.382,20053,643176,178Sep 02 11:48 AM
Welgus Howard G.DirectorAug 20Option Exercise1.685,0008,400176,178Aug 21 02:19 PM
Welgus Howard G.DirectorAug 18Option Exercise1.685,0768,528171,178Aug 19 05:48 PM
Welgus Howard G.DirectorAug 14Option Exercise0.586,1103,545166,102Aug 18 04:12 PM
Welgus Howard G.DirectorAug 03Option Exercise1.682,8004,704162,725Aug 05 05:11 PM
Welgus Howard G.DirectorAug 03Sale25.632,80071,764159,992Aug 05 05:11 PM
Smither John WChief Financial OfficerJun 11Option Exercise1.6814,87524,999123,840Jun 15 03:15 PM
LOGC LogicBio Therapeutics, Inc. daily Stock Chart
LOGC [NASD]
LogicBio Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.60 Insider Own0.10% Shs Outstand23.60M Perf Week9.65%
Market Cap200.60M Forward P/E- EPS next Y-1.39 Insider Trans121.44% Shs Float15.40M Perf Month20.26%
Income-37.20M PEG- EPS next Q-0.34 Inst Own45.20% Short Float3.26% Perf Quarter0.30%
Sales2.90M P/S69.17 EPS this Y41.50% Inst Trans-5.29% Short Ratio2.60 Perf Half Y-8.85%
Book/sh0.94 P/B7.01 EPS next Y5.40% ROA-76.80% Target Price- Perf Year-19.63%
Cash/sh- P/C- EPS next 5Y- ROE-117.60% 52W Range3.05 - 11.60 Perf YTD-8.47%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.17% Beta-
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low116.07% ATR0.43
Employees41 Current Ratio6.20 Sales Q/Q- Oper. Margin- RSI (14)52.40 Volatility5.59% 7.44%
OptionableNo Debt/Eq0.45 EPS Q/Q29.20% Profit Margin- Rel Volume0.18 Prev Close6.31
ShortableYes LT Debt/Eq0.40 Earnings- Payout- Avg Volume192.86K Price6.59
Recom1.50 SMA209.88% SMA504.74% SMA200-4.36% Volume35,045 Change4.44%
May-01-19Initiated ROTH Capital Buy $26
Nov-12-20 04:05PM  
Nov-09-20 06:30AM  
Nov-04-20 07:45AM  
Nov-03-20 04:05PM  
Oct-31-20 08:00AM  
Oct-05-20 11:12AM  
Oct-01-20 09:10AM  
Sep-30-20 04:01PM  
Sep-29-20 11:21AM  
Sep-25-20 07:49PM  
07:47PM  
Sep-14-20 12:59PM  
Aug-10-20 06:35AM  
06:30AM  
Jul-20-20 10:58AM  
Jun-05-20 07:00AM  
Jun-03-20 09:24PM  
May-28-20 07:00AM  
May-18-20 12:15PM  
11:56AM  
10:28AM  
May-17-20 07:45PM  
04:46PM  
02:23PM  
01:00PM  
May-16-20 03:05PM  
09:47AM  
May-15-20 01:25PM  
01:15PM  
12:54PM  
09:56AM  
09:46AM  
May-14-20 03:50PM  
01:00PM  
09:37AM  
May-13-20 08:40PM  
12:56PM  
09:51AM  
May-12-20 10:25PM  
02:15PM  
09:37AM  
08:17AM  
May-11-20 08:10PM  
04:10PM  
04:05PM  
12:53PM  
May-10-20 01:30PM  
12:20PM  
May-08-20 06:15PM  
May-07-20 03:15PM  
10:28AM  
May-06-20 04:50PM  
01:01PM  
May-05-20 07:45PM  
04:15PM  
May-04-20 01:55PM  
May-03-20 09:30AM  
May-01-20 06:15PM  
12:47PM  
Apr-30-20 05:37PM  
Apr-29-20 09:30PM  
08:05PM  
05:00PM  
Apr-28-20 11:00AM  
Apr-27-20 02:37PM  
Apr-25-20 03:45PM  
Apr-23-20 11:06PM  
Apr-22-20 10:29AM  
Apr-18-20 06:08PM  
Apr-15-20 09:35PM  
06:14PM  
04:15PM  
Apr-13-20 09:10PM  
Apr-12-20 01:20PM  
12:40PM  
Apr-10-20 12:22AM  
Apr-07-20 08:00PM  
05:20PM  
06:40AM  
Apr-06-20 10:32AM  
Apr-03-20 06:10AM  
Apr-02-20 03:06PM  
09:56AM  
Apr-01-20 07:27PM  
07:00PM  
Mar-31-20 10:00PM  
Mar-28-20 09:55PM  
11:41AM  
Mar-27-20 04:50PM  
01:17PM  
01:10PM  
10:01AM  
Mar-26-20 12:00PM  
Mar-25-20 06:30PM  
12:58PM  
10:01AM  
Mar-24-20 01:45PM  
10:00AM  
Mar-23-20 05:00PM  
01:30PM  
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was founded in 2014 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLCDirectorOct 01Buy6.001,481,4828,888,8924,126,972Oct 05 05:36 PM
Chimovits ErezDirectorOct 01Buy6.001,481,4828,888,8924,126,972Oct 05 05:32 PM
Arix Bioscience plc10% OwnerSep 28Sale7.54273,5842,061,8662,381,436Oct 05 05:00 PM
Arix Bioscience plc10% OwnerSep 25Sale7.08174,2191,232,9482,655,020Oct 05 05:00 PM
Arix Bioscience plc10% OwnerSep 24Sale7.6338,514293,8232,829,239Oct 05 05:00 PM
Arix Bioscience plc10% OwnerAug 13Sale8.751591,3912,867,753Oct 05 05:00 PM
Arix Bioscience plc10% OwnerAug 12Sale8.791,33511,7352,867,912Oct 05 05:00 PM
Arix Bioscience plc10% OwnerJul 29Sale8.782,70923,7882,869,247Oct 05 05:00 PM
Arix Bioscience plc10% OwnerJul 22Sale9.0022,651203,9502,871,956Oct 05 05:00 PM
Arix Bioscience plc10% OwnerJul 20Sale9.2536,983342,0562,894,607Oct 05 05:00 PM
Arix Bioscience plc10% OwnerJul 17Sale9.2431,101287,3732,931,590Oct 05 05:00 PM
Arix Bioscience plc10% OwnerJul 16Sale8.5616,332139,7862,962,691Oct 05 05:00 PM
PRLD Prelude Therapeutics Incorporated daily Stock Chart
PRLD [NASD]
Prelude Therapeutics Incorporated
Index- P/E- EPS (ttm)- Insider Own4.60% Shs Outstand43.70M Perf Week-13.25%
Market Cap1.98B Forward P/E- EPS next Y-2.01 Insider Trans0.00% Shs Float7.50M Perf Month32.42%
Income- PEG- EPS next Q-0.50 Inst Own76.30% Short Float5.73% Perf Quarter-
Sales- P/S- EPS this Y-87.80% Inst Trans- Short Ratio1.80 Perf Half Y-
Book/sh71.47 P/B0.67 EPS next Y42.90% ROA- Target Price45.00 Perf Year-
Cash/sh5.65 P/C8.44 EPS next 5Y30.10% ROE- 52W Range23.69 - 57.67 Perf YTD81.95%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-17.34% Beta-
Dividend %- Quick Ratio21.00 Sales past 5Y- Gross Margin- 52W Low101.20% ATR4.33
Employees51 Current Ratio21.00 Sales Q/Q- Oper. Margin- RSI (14)57.86 Volatility9.37% 10.45%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.17 Prev Close45.35
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume238.31K Price47.67
Recom3.00 SMA207.91% SMA5022.84% SMA20022.84% Volume40,171 Change5.12%
Nov-20-20Downgrade BofA Securities Buy → Neutral $40 → $60
Oct-20-20Initiated Morgan Stanley Equal-Weight $34
Oct-20-20Initiated Goldman Neutral $37
Oct-20-20Initiated BofA Securities Buy $40
Nov-10-20 07:30AM  
Oct-02-20 08:00PM  
Oct-01-20 11:57AM  
Sep-30-20 07:00AM  
Sep-29-20 04:05PM  
Sep-25-20 02:31PM  
08:47AM  
Sep-24-20 08:50PM  
10:52AM  
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
GRAY Graybug Vision, Inc. daily Stock Chart
GRAY [NASD]
Graybug Vision, Inc.
Index- P/E- EPS (ttm)-2.27 Insider Own5.44% Shs Outstand22.65M Perf Week-12.18%
Market Cap532.28M Forward P/E- EPS next Y-2.28 Insider Trans0.00% Shs Float19.84M Perf Month62.07%
Income-43.40M PEG- EPS next Q-0.40 Inst Own81.80% Short Float1.73% Perf Quarter-
Sales- P/S- EPS this Y-34.90% Inst Trans- Short Ratio1.92 Perf Half Y-
Book/sh- P/B- EPS next Y42.70% ROA- Target Price33.25 Perf Year-
Cash/sh0.77 P/C30.42 EPS next 5Y- ROE- 52W Range12.50 - 37.88 Perf YTD42.42%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.96% Beta-
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin- 52W Low88.00% ATR3.43
Employees24 Current Ratio2.50 Sales Q/Q- Oper. Margin- RSI (14)52.74 Volatility22.00% 16.71%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.40 Prev Close25.37
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume178.48K Price23.50
Recom1.50 SMA204.38% SMA5028.37% SMA20028.37% Volume71,703 Change-7.37%
Oct-20-20Initiated Wedbush Outperform $41
Oct-20-20Initiated SVB Leerink Outperform $35
Oct-20-20Initiated Piper Sandler Overweight $27
Oct-20-20Initiated Oppenheimer Outperform $41
Oct-20-20Initiated Needham Buy $30
Nov-16-20 04:05PM  
Nov-12-20 04:05PM  
Oct-27-20 07:48PM  
Oct-14-20 04:42AM  
Oct-01-20 11:57AM  
Sep-25-20 02:31PM  
12:43PM  
08:00AM  
Sep-24-20 08:12PM  
Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.
PMVP PMV Pharmaceuticals, Inc. daily Stock Chart
PMVP [NASD]
PMV Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)- Insider Own7.40% Shs Outstand44.77M Perf Week10.51%
Market Cap1.54B Forward P/E- EPS next Y-2.29 Insider Trans0.00% Shs Float22.33M Perf Month-0.09%
Income- PEG- EPS next Q-0.57 Inst Own69.80% Short Float6.19% Perf Quarter-
Sales- P/S- EPS this Y-44.60% Inst Trans- Short Ratio4.88 Perf Half Y-
Book/sh61.27 P/B0.57 EPS next Y-11.20% ROA- Target Price45.33 Perf Year-
Cash/sh8.51 P/C4.14 EPS next 5Y23.80% ROE- 52W Range31.05 - 42.93 Perf YTD-6.13%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-17.99% Beta-
Dividend %- Quick Ratio68.20 Sales past 5Y- Gross Margin- 52W Low13.40% ATR2.08
Employees39 Current Ratio68.20 Sales Q/Q- Oper. Margin- RSI (14)54.93 Volatility6.86% 5.68%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.16 Prev Close34.48
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume283.15K Price35.21
Recom2.00 SMA202.56% SMA500.97% SMA2000.97% Volume44,526 Change2.12%
Oct-20-20Initiated Goldman Neutral $34
Oct-20-20Initiated Evercore ISI Outperform $60
Oct-20-20Initiated Cowen Outperform
Oct-20-20Initiated BofA Securities Buy $42
Nov-24-20 05:00PM  
Nov-23-20 08:00AM  
Nov-13-20 08:00AM  
Oct-13-20 08:00AM  
Oct-09-20 03:41PM  
Oct-01-20 11:57AM  
Sep-29-20 04:05PM  
Sep-25-20 02:31PM  
12:37PM  
06:16AM  
Sep-24-20 08:06PM  
PMV Pharmaceuticals, Inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mack David HenryPresident and CEONov 18Option Exercise0.532,4701,3092,470Nov 20 04:12 PM
ETNB 89bio, Inc. daily Stock Chart
ETNB [NASD]
89bio, Inc.
Index- P/E- EPS (ttm)-3.88 Insider Own0.60% Shs Outstand16.88M Perf Week5.04%
Market Cap537.42M Forward P/E- EPS next Y-3.88 Insider Trans- Shs Float8.44M Perf Month13.57%
Income-56.20M PEG- EPS next Q-0.87 Inst Own99.60% Short Float3.65% Perf Quarter-28.68%
Sales- P/S- EPS this Y-210.60% Inst Trans38.94% Short Ratio1.53 Perf Half Y11.94%
Book/sh12.67 P/B2.15 EPS next Y-24.40% ROA-46.50% Target Price- Perf Year-9.43%
Cash/sh11.13 P/C2.45 EPS next 5Y16.00% ROE-49.60% 52W Range14.00 - 47.25 Perf YTD3.77%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-42.27% Beta-
Dividend %- Quick Ratio23.60 Sales past 5Y- Gross Margin- 52W Low94.86% ATR1.24
Employees25 Current Ratio23.60 Sales Q/Q- Oper. Margin- RSI (14)59.00 Volatility3.87% 5.08%
OptionableYes Debt/Eq0.00 EPS Q/Q44.30% Profit Margin- Rel Volume0.45 Prev Close27.04
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume200.79K Price27.28
Recom1.40 SMA206.86% SMA509.29% SMA200-2.25% Volume89,539 Change0.89%
Oct-19-20Initiated Raymond James Strong Buy $65
Sep-25-20Upgrade BofA Securities Neutral → Buy $37 → $43
Jul-31-20Initiated Piper Sandler Overweight $54
Jul-23-20Initiated BTIG Research Buy
Jul-07-20Initiated Chardan Capital Markets Buy $58
Dec-09-19Initiated SVB Leerink Outperform
Dec-09-19Initiated RBC Capital Mkts Outperform
Dec-09-19Initiated Oppenheimer Outperform
Dec-09-19Initiated BofA/Merrill Neutral
Nov-24-20 08:00AM  
Nov-13-20 08:00AM  
Nov-10-20 04:02PM  
Nov-08-20 09:29AM  
Nov-02-20 08:00AM  
Sep-28-20 05:18PM  
Sep-23-20 07:00AM  
Sep-16-20 08:51PM  
Sep-14-20 05:21PM  
07:01AM  
Sep-13-20 07:53PM  
Sep-03-20 08:30AM  
Aug-13-20 04:05PM  
Aug-11-20 08:32AM  
Aug-10-20 12:15PM  
12:09PM  
Aug-03-20 04:05PM  
Jul-24-20 06:12PM  
Jul-13-20 10:18AM  
Jul-10-20 08:26AM  
Jul-07-20 09:30PM  
Jul-06-20 06:30AM  
Jun-04-20 08:00AM  
May-27-20 05:26PM  
May-13-20 04:05PM  
May-08-20 07:30AM  
Apr-13-20 08:30AM  
Mar-25-20 04:05PM  
Mar-18-20 04:05PM  
Feb-21-20 04:05PM  
Feb-11-20 06:43AM  
Dec-18-19 04:05PM  
Nov-13-19 04:02PM  
Nov-11-19 09:25AM  
08:22AM  
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Le-Nguyen QuocSee RemarksNov 16Option Exercise3.114,54814,1444,548Nov 18 04:00 PM
Waisbourd RamCOO and Chief Business OfficerNov 16Option Exercise1.937,00013,5107,000Nov 18 04:00 PM
Waisbourd RamCOO and Chief Business OfficerNov 16Sale27.397,000191,7300Nov 18 04:00 PM
Le-Nguyen QuocSee RemarksNov 16Sale28.114,548127,8440Nov 18 04:00 PM
ORBIMED ADVISORS LLCDirectorSep 21Sale28.00275,0007,700,0001,864,721Sep 23 05:09 PM
Naschitz AnatDirectorSep 21Sale28.00275,0007,700,0001,864,721Sep 23 05:04 PM
RA CAPITAL MANAGEMENT, L.P.DirectorSep 17Buy28.001,300,00036,400,0004,736,214Sep 21 04:30 PM
Longitude Capital Partners III10% OwnerJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:11 PM
Grunberg GregoryDirectorJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:08 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 08Buy27.50275,0007,562,5003,436,214Jul 10 04:32 PM
INSP Inspire Medical Systems, Inc. daily Stock Chart
INSP [NYSE]
Inspire Medical Systems, Inc.
Index- P/E- EPS (ttm)-2.32 Insider Own0.60% Shs Outstand26.84M Perf Week3.70%
Market Cap4.90B Forward P/E- EPS next Y-2.27 Insider Trans-87.51% Shs Float25.92M Perf Month54.16%
Income-58.80M PEG- EPS next Q-0.48 Inst Own- Short Float4.38% Perf Quarter57.94%
Sales96.30M P/S50.91 EPS this Y-49.70% Inst Trans-3.02% Short Ratio3.62 Perf Half Y121.94%
Book/sh8.53 P/B21.69 EPS next Y5.40% ROA-26.40% Target Price161.75 Perf Year158.73%
Cash/sh8.85 P/C20.90 EPS next 5Y4.80% ROE-32.20% 52W Range40.53 - 186.92 Perf YTD149.28%
Dividend- P/FCF- EPS past 5Y- ROI-21.30% 52W High-1.03% Beta-
Dividend %- Quick Ratio14.20 Sales past 5Y- Gross Margin84.70% 52W Low356.43% ATR6.86
Employees239 Current Ratio14.70 Sales Q/Q71.30% Oper. Margin-60.80% RSI (14)72.90 Volatility2.73% 4.56%
OptionableYes Debt/Eq0.11 EPS Q/Q-12.30% Profit Margin-61.10% Rel Volume0.29 Prev Close181.98
ShortableYes LT Debt/Eq0.11 EarningsNov 02 AMC Payout- Avg Volume313.26K Price184.99
Recom1.70 SMA2011.08% SMA5029.73% SMA20084.29% Volume89,773 Change1.65%
Nov-03-20Upgrade Oppenheimer Underperform → Perform
Nov-03-20Upgrade BofA Securities Neutral → Buy $125 → $155
Sep-22-20Initiated JP Morgan Overweight $148
Sep-02-20Initiated Robert W. Baird Outperform $130
Aug-06-20Downgrade BofA Securities Buy → Neutral $115
Jul-15-20Initiated Goldman Buy $148
Jun-18-20Reiterated Piper Sandler Overweight $81 → $98
May-18-20Initiated Lake Street Buy $90
Apr-28-20Upgrade BofA/Merrill Neutral → Buy $90
Apr-09-20Initiated Piper Sandler Overweight $74
Jan-28-20Initiated Oppenheimer Underperform
Jan-27-20Initiated Oppenheimer Underperform
Nov-06-19Upgrade Berenberg Sell → Hold $46 → $51
Feb-05-19Initiated Dougherty & Company Buy $64
Nov-28-18Initiated Berenberg Sell $31
Oct-29-18Initiated Leerink Partners Outperform $57
May-29-18Initiated Wells Fargo Outperform
May-29-18Initiated Stifel Buy $42
May-29-18Initiated Guggenheim Buy $40
May-29-18Initiated Goldman Neutral $25
Nov-18-20 08:00AM  
Nov-10-20 08:00AM  
Nov-09-20 04:05PM  
Nov-05-20 06:44AM  
Nov-03-20 04:23PM  
Nov-02-20 05:35PM  
04:39PM  
04:05PM  
03:15PM  
Oct-27-20 04:05PM  
Oct-26-20 12:31PM  
Oct-22-20 08:00AM  
Oct-02-20 06:50PM  
Sep-29-20 08:45AM  
Sep-24-20 08:00AM  
Sep-02-20 04:05PM  
10:20AM  
Sep-01-20 07:00AM  
Aug-17-20 04:05PM  
Aug-12-20 04:05PM  
Aug-07-20 02:11PM  
Aug-04-20 06:15PM  
05:28PM  
04:05PM  
Jul-28-20 12:33PM  
Jul-21-20 09:56AM  
Jul-20-20 04:02PM  
Jul-09-20 04:05PM  
Jul-07-20 08:00AM  
Jun-16-20 04:05PM  
03:09PM  
Jun-15-20 08:58AM  
Jun-08-20 08:00AM  
Jun-03-20 04:05PM  
Jun-01-20 04:05PM  
May-11-20 07:00AM  
May-07-20 01:54PM  
May-06-20 04:05PM  
12:02PM  
May-05-20 07:25PM  
04:10PM  
03:00PM  
May-04-20 08:50AM  
Apr-30-20 04:05PM  
Apr-28-20 12:33PM  
07:00AM  
Apr-21-20 07:00AM  
Apr-16-20 04:05PM  
Apr-15-20 02:49PM  
09:03AM  
Apr-13-20 09:27PM  
04:19PM  
04:01PM  
Apr-09-20 10:46AM  
Feb-25-20 06:25PM  
04:15PM  
Feb-24-20 08:36AM  
Feb-12-20 04:05PM  
Feb-07-20 06:10AM  
Feb-03-20 04:22PM  
Jan-28-20 04:05PM  
Jan-19-20 09:16AM  
Jan-07-20 04:05PM  
Dec-24-19 12:47PM  
Nov-20-19 04:05PM  
Nov-06-19 04:15PM  
Nov-05-19 06:45PM  
04:10PM  
Oct-29-19 10:32AM  
Oct-26-19 12:36PM  
Oct-21-19 10:44AM  
Oct-08-19 04:15PM  
Sep-26-19 04:30PM  
Sep-10-19 07:15PM  
Aug-29-19 04:05PM  
Aug-28-19 06:15PM  
Aug-26-19 10:03AM  
08:00AM  
Aug-22-19 09:08AM  
Aug-21-19 04:05PM  
Aug-19-19 01:21PM  
Aug-15-19 08:00AM  
Aug-13-19 08:00AM  
Aug-12-19 02:00AM  
Aug-09-19 12:20PM  
Aug-07-19 06:23AM  
Aug-06-19 06:15PM  
04:15PM  
Aug-05-19 07:15PM  
Jul-30-19 10:38AM  
Jul-25-19 04:05PM  
Jul-09-19 04:05PM  
Jul-08-19 10:14AM  
06:50AM  
Jul-01-19 08:00AM  
Jun-19-19 08:57AM  
May-14-19 04:16PM  
May-08-19 04:44PM  
07:23AM  
May-07-19 07:05PM  
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was founded in 2007 and is headquartered in Golden Valley, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Buchholz RichardChief Financial OfficerNov 17Sale171.663,000514,98668,651Nov 19 04:15 PM
Herbert Timothy P.CEO and PresidentNov 05Sale163.7480,00013,099,424122,875Nov 09 04:15 PM
NELSON MARILYN CDirectorNov 03Sale144.657,0001,012,550138,017Nov 05 04:19 PM
Buchholz RichardChief Financial OfficerOct 20Sale122.843,000368,51071,651Oct 22 04:19 PM
Buchholz RichardChief Financial OfficerOct 09Option Exercise29.948,267247,48974,651Oct 13 08:00 AM
NELSON MARILYN CDirectorOct 09Sale130.001,000130,000145,017Oct 16 05:38 PM
NELSON MARILYN CDirectorOct 08Sale130.9625,0003,273,977146,017Oct 16 05:38 PM
Buchholz RichardChief Financial OfficerSep 22Sale126.096,000756,55666,384Sep 24 04:17 PM
Tansey Casey MDirectorSep 14Sale129.2712,0001,551,21118,830Sep 16 05:47 PM
Ban RandyChief Commercial OfficerSep 09Option Exercise1.1430,00034,20030,189Sep 11 04:15 PM
Ban RandyChief Commercial OfficerSep 09Sale117.5430,0003,526,268189Sep 11 04:15 PM
Griffin Jerry CDirectorAug 27Sale115.3428,8003,321,7320Aug 28 04:15 PM
Jandrich StevenChief Comp Off & VP, Human ResAug 18Option Exercise31.703,00095,0934,805Aug 20 04:15 PM
Jandrich StevenChief Comp Off & VP, Human ResAug 18Sale110.003,000330,0001,805Aug 20 04:15 PM
Khuong Chau QuangDirectorAug 18Sale108.5443,5434,726,1570Aug 19 05:19 PM
ORBIMED ADVISORS LLCDirectorAug 18Sale108.5443,5434,726,1570Aug 19 05:24 PM
ORBIMED ADVISORS LLCDirectorAug 17Sale107.4994,90010,200,80143,543Aug 19 05:24 PM
Khuong Chau QuangDirectorAug 17Sale107.4994,90010,200,80143,543Aug 19 05:19 PM
Khuong Chau QuangDirectorAug 14Sale109.0320,2372,206,440138,443Aug 14 05:22 PM
ORBIMED ADVISORS LLCDirectorAug 14Sale109.0320,2572,208,621138,443Aug 14 05:19 PM
ORBIMED ADVISORS LLCDirectorAug 13Sale109.9329,2513,215,562158,500Aug 14 05:19 PM
Khuong Chau QuangDirectorAug 13Sale109.9329,2513,215,562158,500Aug 14 05:22 PM
Khuong Chau QuangDirectorAug 12Sale107.4542,6794,585,859187,751Aug 14 05:22 PM
ORBIMED ADVISORS LLCDirectorAug 12Sale107.4542,6794,585,859187,751Aug 14 05:19 PM
ORBIMED ADVISORS LLCDirectorAug 11Sale105.7839,8774,218,189230,430Aug 11 06:23 PM
Khuong Chau QuangDirectorAug 11Sale105.7839,8774,218,189230,430Aug 11 06:19 PM
Khuong Chau QuangDirectorAug 10Sale105.2347,7005,019,471270,307Aug 11 06:19 PM
ORBIMED ADVISORS LLCDirectorAug 10Sale105.2347,7005,019,471270,307Aug 11 06:23 PM
ORBIMED ADVISORS LLCDirectorAug 07Sale106.1828,9933,078,477318,007Aug 11 06:23 PM
Khuong Chau QuangDirectorAug 07Sale106.1828,9933,078,477318,007Aug 11 06:19 PM
Herbert Timothy P.CEO and PresidentAug 06Sale105.6680,0008,452,716202,875Aug 10 06:22 PM
Buchholz RichardChief Financial OfficerJul 22Option Exercise6.2642,436265,75573,504Jul 23 04:16 PM
Jandrich StevenChief Comp Off & VP, Human ResJul 21Option Exercise0.941,0009402,805Jul 23 04:17 PM
Buchholz RichardChief Financial OfficerJul 21Option Exercise2.073,0006,21034,068Jul 23 04:16 PM
Jandrich StevenChief Comp Off & VP, Human ResJul 21Sale98.961,00098,9601,805Jul 23 04:17 PM
Buchholz RichardChief Financial OfficerJul 21Sale99.373,000298,12231,068Jul 23 04:16 PM
Jandrich StevenChief Comp Off & VP, Human ResJun 23Option Exercise0.941,0009402,805Jun 25 06:01 PM
Buchholz RichardChief Financial OfficerJun 23Option Exercise2.0712,00024,84042,871Jun 25 06:01 PM
Buchholz RichardChief Financial OfficerJun 23Sale97.2512,0001,167,00830,871Jun 25 06:01 PM
Jandrich StevenChief Comp Off & VP, Human ResJun 23Sale96.391,00096,3901,805Jun 25 06:01 PM
NELSON MARILYN CDirectorJun 16Sale87.9410,000879,409176,517Jun 18 09:07 PM
NELSON MARILYN CDirectorJun 15Sale82.3625,0002,059,081186,517Jun 18 09:07 PM
Tansey Casey MDirectorJun 15Sale84.04100,0008,404,25530,681Jun 17 04:15 PM
Jandrich StevenChief Comp Off & VP, Human ResMay 19Option Exercise0.941,0009402,805May 20 04:15 PM
Jandrich StevenChief Comp Off & VP, Human ResMay 19Sale80.001,00080,0001,805May 20 04:15 PM
Jandrich StevenChief Comp Off & VP, Human ResApr 21Option Exercise0.942,0001,8803,805Apr 23 04:31 PM
Jandrich StevenChief Comp Off & VP, Human ResApr 21Sale72.682,000145,3601,805Apr 23 04:31 PM
Ban RandyChief Commercial OfficerApr 09Option Exercise1.1410,00011,40010,142Apr 10 05:05 PM
Ban RandyChief Commercial OfficerApr 09Sale64.0010,000640,000142Apr 10 05:05 PM
Herbert Timothy P.CEO and PresidentMar 17Option Exercise0.97178,786174,274178,786Mar 19 06:07 PM
Khuong Chau QuangDirectorMar 06Sale83.52500,00041,760,000347,000Mar 10 05:08 PM
ORBIMED ADVISORS LLCDirectorMar 06Sale83.52500,00041,760,000347,000Mar 10 05:06 PM
Ban RandyChief Commercial OfficerMar 04Option Exercise1.1410,00011,40010,000Mar 06 06:16 PM
Ban RandyChief Commercial OfficerMar 04Sale86.5510,000865,4650Mar 06 06:16 PM
Khuong Chau QuangDirectorMar 04Sale84.43425,00035,881,750847,000Mar 05 06:37 PM
Khuong Chau QuangDirectorMar 03Sale83.2175,0006,240,7501,272,000Mar 05 06:37 PM
ORBIMED ADVISORS LLCDirectorMar 03Sale84.25500,00042,122,500847,000Mar 05 06:34 PM
Tansey Casey MDirectorFeb 28Sale83.1470,0005,819,938130,469Mar 03 04:15 PM
Ban RandyChief Commercial OfficerFeb 04Option Exercise1.1410,00011,40010,000Feb 06 06:01 PM
Ban RandyChief Commercial OfficerFeb 04Sale76.2110,000762,0750Feb 06 06:01 PM
Griffin Jerry CDirectorJan 22Sale80.931,312106,18028,800Jan 23 04:15 PM
Griffin Jerry CDirectorJan 21Sale81.925,000409,58730,112Jan 23 04:15 PM
Herbert Timothy P.CEO and PresidentJan 14Sale80.0015,1681,213,44015,324Jan 15 04:52 PM
Herbert Timothy P.CEO and PresidentJan 13Sale80.109,832787,52830,492Jan 15 04:52 PM
Jain Mudit K.DirectorJan 08Sale76.9750038,485820Jan 08 06:14 PM
Griffin Jerry CDirectorJan 07Sale75.185,000375,88635,112Jan 08 04:51 PM
Jain Mudit K.DirectorJan 06Sale75.9750037,9851,320Jan 08 06:14 PM
Griffin Jerry CDirectorJan 06Sale74.135,000370,64140,112Jan 08 04:51 PM
Griffin Jerry CDirectorDec 18Sale71.2110,000712,08045,112Dec 20 04:15 PM
Jain Mudit K.DirectorDec 06Sale74.9750037,4851,820Dec 10 04:48 PM
NELSON MARILYN CDirectorDec 06Sale75.0515,0001,125,750211,517Dec 10 04:48 PM
Jain Mudit K.DirectorDec 04Sale74.3930022,3172,320Dec 06 04:15 PM
AFIB Acutus Medical, Inc. daily Stock Chart
AFIB [NASD]
Acutus Medical, Inc.
Index- P/E- EPS (ttm)- Insider Own2.30% Shs Outstand16.08M Perf Week12.82%
Market Cap764.71M Forward P/E- EPS next Y-3.04 Insider Trans0.00% Shs Float15.34M Perf Month14.99%
Income- PEG- EPS next Q-0.84 Inst Own87.40% Short Float13.63% Perf Quarter-7.07%
Sales6.56M P/S116.59 EPS this Y-102.60% Inst Trans- Short Ratio10.61 Perf Half Y-
Book/sh9.49 P/B3.03 EPS next Y44.50% ROA- Target Price36.75 Perf Year-
Cash/sh5.94 P/C4.84 EPS next 5Y- ROE- 52W Range22.26 - 38.99 Perf YTD8.57%
Dividend- P/FCF- EPS past 5Y- ROI42.60% 52W High-26.21% Beta-
Dividend %- Quick Ratio10.20 Sales past 5Y- Gross Margin- 52W Low29.25% ATR1.63
Employees224 Current Ratio10.90 Sales Q/Q300.00% Oper. Margin- RSI (14)60.41 Volatility7.42% 6.53%
OptionableNo Debt/Eq0.30 EPS Q/Q-226.20% Profit Margin- Rel Volume0.13 Prev Close27.46
ShortableYes LT Debt/Eq0.28 EarningsNov 12 AMC Payout- Avg Volume197.03K Price28.77
Recom1.60 SMA2015.95% SMA507.41% SMA2002.50% Volume24,703 Change4.77%
Aug-31-20Initiated William Blair Outperform
Aug-31-20Initiated JP Morgan Overweight $39
Aug-31-20Initiated Canaccord Genuity Hold $30
Aug-31-20Initiated BTIG Research Buy $40
Aug-31-20Initiated BofA Securities Buy $38
Nov-12-20 04:02PM  
04:01PM  
03:15PM  
Nov-05-20 04:01PM  
Oct-29-20 04:01PM  
Sep-17-20 04:01PM  
04:01PM  
02:30PM  
Sep-08-20 08:30AM  
Sep-03-20 04:01PM  
Aug-20-20 04:58PM  
Aug-10-20 04:41PM  
Aug-05-20 08:30PM  
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. It offers AcQMap console and workstation, an advanced imaging, navigation, and mapping system for physicians to map, treat, re-map, and adjust additional therapy as needed; and Patient Electrode Kit that is required in every procedure to provide cardiac signals, catheter localization, and AcQMap system grounding. The company also provides diagnostic and monitoring devices, such as AcQMap 3D Imaging and Mapping Catheter that is used for mapping during the electrophysiology procedures; conventional diagnostic catheters, including multi-polar, steerable, and loop catheters that are used during the mapping and ablation procedures; and reprocessed diagnostic catheters, such as diagnostic, multipole, fixed, steerable, and advanced mapping and imaging catheters. In addition, the company provides access devices, which include AcQRef Introducer that provides stable electrical reference and vascular access; AcQGuide MAX Steerable Introducer, which provides a stable platform for catheter passage and precision placement; and Transseptal Access Products. Further, it offers therapeutic devices, such as AcQBlate FORCE Ablation Catheters, AlCath Ablation Catheters, MedFact Robotic Navigation Enabled Ablation Catheters, Qubic Force, Qubic RF Generator and Pulse Stimulator, and Qiona Pump. The company also provides various software mapping modes comprises single position, supermap, contact mapping, and stereotaxis integration. Acutus Medical, Inc. was founded in 2011 and is based in Carlsbad, California.
FUSN Fusion Pharmaceuticals Inc. daily Stock Chart
FUSN [NASD]
Fusion Pharmaceuticals Inc.
Index- P/E- EPS (ttm)- Insider Own9.00% Shs Outstand41.68M Perf Week-4.03%
Market Cap521.62M Forward P/E- EPS next Y-0.25 Insider Trans0.00% Shs Float31.91M Perf Month0.98%
Income- PEG- EPS next Q-0.22 Inst Own76.00% Short Float0.73% Perf Quarter-4.40%
Sales- P/S- EPS this Y-38.90% Inst Trans-6.69% Short Ratio6.93 Perf Half Y-
Book/sh7.35 P/B1.69 EPS next Y79.30% ROA- Target Price- Perf Year-
Cash/sh6.94 P/C1.79 EPS next 5Y- ROE- 52W Range11.50 - 19.00 Perf YTD-27.12%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-34.79% Beta-
Dividend %- Quick Ratio55.90 Sales past 5Y- Gross Margin- 52W Low7.74% ATR0.61
Employees41 Current Ratio55.90 Sales Q/Q- Oper. Margin- RSI (14)46.32 Volatility5.80% 5.32%
OptionableNo Debt/Eq0.00 EPS Q/Q-189.00% Profit Margin- Rel Volume0.28 Prev Close12.50
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume33.69K Price12.39
Recom1.50 SMA20-4.07% SMA50-1.11% SMA200-7.31% Volume9,573 Change-0.88%
Jul-21-20Initiated Wedbush Outperform $25
Jul-21-20Initiated Jefferies Buy $25
Jul-21-20Initiated Cowen Outperform
Nov-26-20 12:36AM  
Nov-12-20 04:10PM  
04:10PM  
02:05PM  
Nov-10-20 07:00AM  
07:00AM  
Nov-02-20 04:10PM  
07:00AM  
Oct-27-20 03:30PM  
Oct-11-20 09:30AM  
Sep-29-20 04:15PM  
Sep-27-20 10:18AM  
Sep-10-20 09:00AM  
Aug-11-20 07:25AM  
Aug-05-20 08:00AM  
Jul-14-20 09:30AM  
Jul-10-20 05:13PM  
Jun-25-20 10:39PM  
10:39PM  
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
RPTX Repare Therapeutics Inc. daily Stock Chart
RPTX [NASD]
Repare Therapeutics Inc.
Index- P/E- EPS (ttm)- Insider Own0.50% Shs Outstand36.76M Perf Week7.87%
Market Cap1.12B Forward P/E- EPS next Y-2.07 Insider Trans0.00% Shs Float36.12M Perf Month18.62%
Income- PEG- EPS next Q-0.39 Inst Own84.80% Short Float2.49% Perf Quarter24.90%
Sales- P/S- EPS this Y-90.60% Inst Trans2.76% Short Ratio11.94 Perf Half Y-
Book/sh8.18 P/B3.67 EPS next Y1.00% ROA- Target Price36.80 Perf Year-
Cash/sh9.34 P/C3.21 EPS next 5Y- ROE- 52W Range21.45 - 36.67 Perf YTD-2.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-18.19% Beta-
Dividend %- Quick Ratio35.40 Sales past 5Y- Gross Margin- 52W Low39.86% ATR1.91
Employees79 Current Ratio35.40 Sales Q/Q- Oper. Margin- RSI (14)54.69 Volatility7.43% 6.52%
OptionableNo Debt/Eq0.00 EPS Q/Q-106.00% Profit Margin- Rel Volume0.66 Prev Close30.39
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume75.29K Price30.00
Recom2.20 SMA206.00% SMA507.12% SMA20010.77% Volume49,561 Change-1.28%
Oct-28-20Initiated Northland Capital Outperform $38
Jul-14-20Initiated Piper Sandler Overweight
Jul-14-20Initiated Morgan Stanley Overweight $37
Jul-14-20Initiated Goldman Neutral $27
Jul-14-20Initiated Cowen Outperform
Nov-23-20 07:00AM  
Nov-11-20 04:05PM  
Sep-21-20 03:55PM  
Sep-09-20 07:00AM  
Aug-13-20 04:05PM  
Jul-29-20 06:00AM  
Jul-14-20 09:30AM  
Jul-02-20 07:30PM  
Jun-23-20 04:05PM  
Jun-18-20 09:56PM  
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was founded in 2016 and is headquartered in Montreal, Canada.
SCPH scPharmaceuticals Inc. daily Stock Chart
SCPH [NASD]
scPharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.62 Insider Own0.10% Shs Outstand27.32M Perf Week-0.98%
Market Cap252.71M Forward P/E- EPS next Y-1.76 Insider Trans- Shs Float25.00M Perf Month14.90%
Income-35.20M PEG- EPS next Q-0.40 Inst Own65.80% Short Float0.79% Perf Quarter8.59%
Sales- P/S- EPS this Y-11.80% Inst Trans-2.31% Short Ratio3.84 Perf Half Y5.20%
Book/sh3.29 P/B2.77 EPS next Y-22.20% ROA-35.40% Target Price13.50 Perf Year113.62%
Cash/sh4.12 P/C2.21 EPS next 5Y- ROE-47.90% 52W Range4.01 - 11.99 Perf YTD60.78%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-24.10% Beta-
Dividend %- Quick Ratio16.10 Sales past 5Y- Gross Margin- 52W Low126.93% ATR0.45
Employees26 Current Ratio16.10 Sales Q/Q- Oper. Margin- RSI (14)55.66 Volatility4.60% 4.88%
OptionableNo Debt/Eq0.00 EPS Q/Q0.90% Profit Margin- Rel Volume0.36 Prev Close9.25
ShortableYes LT Debt/Eq0.21 Earnings- Payout- Avg Volume51.43K Price9.10
Recom2.00 SMA201.16% SMA508.13% SMA2008.72% Volume18,518 Change-1.62%
Oct-15-19Initiated H.C. Wainwright Buy $13
Jan-30-19Downgrade Leerink Partners Outperform → Mkt Perform
Nov-19-20 08:00AM  
Nov-16-20 07:00AM  
Nov-11-20 08:00AM  
Oct-08-20 08:00AM  
Oct-01-20 07:19AM  
Sep-17-20 08:00AM  
Sep-03-20 08:00AM  
Aug-28-20 02:27PM  
Aug-13-20 07:00AM  
Jul-27-20 08:00AM  
Jul-10-20 08:00AM  
Jul-01-20 08:00AM  
Jun-23-20 10:50AM  
Jun-18-20 08:00AM  
Jun-12-20 12:28PM  
May-28-20 08:00AM  
May-21-20 02:20PM  
May-20-20 11:18PM  
04:01PM  
May-12-20 07:00AM  
Mar-24-20 07:00AM  
Feb-26-20 08:00AM  
Feb-20-20 08:00AM  
Jan-22-20 10:14AM  
Dec-21-19 07:10PM  
Dec-12-19 08:00AM  
Nov-26-19 08:00AM  
08:00AM  
Nov-22-19 07:15AM  
Nov-14-19 08:00AM  
Nov-12-19 08:00AM  
Sep-18-19 08:00AM  
Aug-07-19 08:00AM  
Aug-06-19 08:00AM  
Jul-26-19 09:32AM  
May-30-19 08:00AM  
May-08-19 08:00AM  
Apr-27-19 10:46AM  
Mar-21-19 08:00AM  
Feb-21-19 08:00AM  
Jan-29-19 08:00AM  
Nov-21-18 08:40AM  
Nov-13-18 08:00AM  
Oct-18-18 07:30AM  
Aug-14-18 08:00AM  
Jul-24-18 08:00AM  
Jun-28-18 08:00AM  
Jun-13-18 08:51AM  
08:00AM  
May-31-18 02:26PM  
08:30AM  
May-30-18 08:00AM  
May-07-18 04:01PM  
Apr-30-18 10:54AM  
Apr-11-18 08:00AM  
Apr-04-18 09:05AM  
Mar-20-18 07:22PM  
Mar-01-18 08:00AM  
Feb-06-18 08:00AM  
Dec-20-17 11:06AM  
Dec-12-17 08:00AM  
Nov-29-17 09:23AM  
08:00AM  
Nov-27-17 02:45PM  
Nov-16-17 09:05PM  
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab Andrew J.10% OwnerMay 26Buy8.65578,0344,999,994578,034May 28 09:12 PM
ORBIMED ADVISORS LLC10% OwnerMay 21Buy8.651,387,28311,999,9984,565,948May 26 04:44 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerFeb 14Buy8.20271,9932,230,3433,247,005Feb 19 04:30 PM
Tucker John HPresident and CEODec 13Buy5.245,00026,1895,000Dec 17 04:16 PM
ORIC ORIC Pharmaceuticals, Inc. daily Stock Chart
ORIC [NASD]
ORIC Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.59 Insider Own1.16% Shs Outstand30.32M Perf Week7.11%
Market Cap1.01B Forward P/E- EPS next Y-2.18 Insider Trans0.00% Shs Float19.00M Perf Month55.02%
Income-53.80M PEG- EPS next Q-0.45 Inst Own73.80% Short Float12.59% Perf Quarter30.14%
Sales- P/S- EPS this Y-25.80% Inst Trans5.61% Short Ratio14.70 Perf Half Y4.88%
Book/sh6.08 P/B5.23 EPS next Y39.40% ROA- Target Price43.57 Perf Year-
Cash/sh5.88 P/C5.40 EPS next 5Y- ROE- 52W Range18.60 - 40.67 Perf YTD23.32%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-21.86% Beta-
Dividend %- Quick Ratio27.30 Sales past 5Y- Gross Margin- 52W Low70.86% ATR2.71
Employees60 Current Ratio27.30 Sales Q/Q- Oper. Margin- RSI (14)66.94 Volatility11.16% 10.91%
OptionableNo Debt/Eq0.00 EPS Q/Q75.00% Profit Margin- Rel Volume1.02 Prev Close28.32
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume162.78K Price31.78
Recom1.30 SMA2025.55% SMA5034.98% SMA20020.23% Volume165,623 Change12.22%
Aug-13-20Initiated Robert W. Baird Outperform $45
Aug-06-20Upgrade Citigroup Neutral → Buy $35
Aug-03-20Initiated H.C. Wainwright Buy $52
May-19-20Initiated JP Morgan Overweight $40
May-19-20Initiated Jefferies Buy $40
May-19-20Initiated Guggenheim Buy $45
May-19-20Initiated Citigroup Neutral $35
Nov-17-20 04:15PM  
Nov-13-20 06:32AM  
Nov-10-20 04:05PM  
Nov-09-20 06:30AM  
Nov-05-20 04:05PM  
Nov-04-20 10:43AM  
Oct-19-20 04:02PM  
Oct-09-20 06:30AM  
Sep-02-20 04:30PM  
Aug-06-20 03:50PM  
Aug-05-20 04:10PM  
04:05PM  
Aug-03-20 10:15PM  
Jun-22-20 09:00AM  
Jun-09-20 04:15PM  
May-27-20 06:30AM  
May-26-20 06:30AM  
May-20-20 04:15PM  
Apr-28-20 04:30PM  
Apr-27-20 04:30PM  
Apr-23-20 08:56PM  
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
ALEC Alector, Inc. daily Stock Chart
ALEC [NASD]
Alector, Inc.
Index- P/E- EPS (ttm)-2.23 Insider Own0.40% Shs Outstand78.77M Perf Week7.61%
Market Cap1.05B Forward P/E- EPS next Y-2.76 Insider Trans-8.85% Shs Float65.55M Perf Month36.87%
Income-168.60M PEG- EPS next Q-0.66 Inst Own78.80% Short Float15.12% Perf Quarter4.24%
Sales22.20M P/S47.44 EPS this Y-125.00% Inst Trans-1.81% Short Ratio11.54 Perf Half Y-59.86%
Book/sh3.94 P/B3.37 EPS next Y-11.30% ROA-31.40% Target Price- Perf Year-29.76%
Cash/sh5.83 P/C2.28 EPS next 5Y- ROE-53.90% 52W Range9.12 - 35.93 Perf YTD-22.87%
Dividend- P/FCF- EPS past 5Y- ROI-58.80% 52W High-63.01% Beta-
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low45.72% ATR0.59
Employees162 Current Ratio6.60 Sales Q/Q118.50% Oper. Margin- RSI (14)67.40 Volatility3.45% 5.48%
OptionableYes Debt/Eq0.00 EPS Q/Q-42.40% Profit Margin- Rel Volume0.30 Prev Close13.29
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume858.75K Price13.29
Recom1.60 SMA2012.10% SMA5019.37% SMA200-35.14% Volume259,807 Change0.00%
Jun-24-20Initiated H.C. Wainwright Buy $41
Apr-28-20Initiated Goldman Buy $32
Mar-06-20Initiated Citigroup Buy $40
Feb-27-20Initiated Barclays Overweight $36
Feb-19-20Initiated Stifel Buy $44
Nov-21-19Initiated BTIG Research Buy $28
Mar-04-19Initiated SVB Leerink Outperform
Mar-04-19Initiated Morgan Stanley Overweight $27
Mar-04-19Initiated BofA/Merrill Buy $26
Mar-04-19Initiated Barclays Overweight $27
Nov-12-20 11:18AM  
Nov-11-20 04:05PM  
Nov-10-20 06:45PM  
04:05PM  
Nov-09-20 05:30AM  
Nov-03-20 12:30PM  
Nov-02-20 07:44AM  
Oct-22-20 04:05PM  
Oct-06-20 08:54AM  
Sep-24-20 11:46AM  
Sep-16-20 03:23PM  
Sep-13-20 08:53AM  
Sep-03-20 04:05PM  
Aug-11-20 05:55PM  
04:05PM  
Aug-04-20 08:30AM  
Aug-03-20 12:31PM  
Jul-29-20 01:00PM  
07:32AM  
Jul-28-20 06:00PM  
Jul-24-20 06:12PM  
08:30AM  
Jul-21-20 05:00PM  
05:00PM  
Jul-15-20 07:31AM  
Jun-28-20 07:16PM  
Jun-25-20 09:00AM  
Jun-12-20 07:00PM  
Jun-03-20 04:01PM  
May-16-20 08:05AM  
May-13-20 09:25AM  
08:00AM  
May-07-20 08:30AM  
May-04-20 08:20AM  
May-03-20 07:00AM  
Apr-02-20 11:30AM  
Mar-31-20 10:34AM  
Mar-26-20 06:11AM  
Mar-25-20 05:00PM  
Mar-24-20 05:25PM  
04:05PM  
Mar-23-20 08:30AM  
Mar-17-20 12:30PM  
12:00PM  
11:30AM  
Mar-11-20 09:53AM  
Mar-06-20 07:25PM  
Feb-28-20 08:51AM  
Feb-24-20 08:30AM  
Feb-06-20 07:47AM  
Feb-05-20 08:00AM  
07:21AM  
Feb-03-20 06:00PM  
Jan-31-20 09:09AM  
08:00AM  
Jan-29-20 09:42PM  
Jan-28-20 08:30AM  
Jan-27-20 04:05PM  
Jan-17-20 08:45PM  
Jan-08-20 08:30AM  
Jan-06-20 08:30AM  
Dec-27-19 02:57PM  
Dec-20-19 08:30AM  
Dec-13-19 06:30AM  
06:28AM  
Dec-12-19 07:08PM  
Dec-11-19 04:05PM  
Dec-06-19 04:30PM  
07:39AM  
Dec-05-19 04:22PM  
Dec-04-19 09:15AM  
Nov-14-19 08:30AM  
Nov-12-19 04:05PM  
Nov-11-19 09:28AM  
Oct-28-19 07:46PM  
Sep-23-19 01:22PM  
Sep-20-19 10:02AM  
Sep-19-19 06:56AM  
Sep-09-19 08:00AM  
Sep-03-19 04:10PM  
Aug-12-19 04:10PM  
09:00AM  
Jul-18-19 10:26AM  
Jul-17-19 04:05PM  
Jul-11-19 06:30AM  
Jun-26-19 09:04PM  
Jun-14-19 12:03PM  
May-13-19 04:26PM  
04:05PM  
May-08-19 04:05PM  
02:15PM  
May-06-19 06:30AM  
May-01-19 05:43PM  
Apr-22-19 12:28AM  
Apr-17-19 04:05PM  
Apr-15-19 03:00PM  
Apr-10-19 08:00AM  
Apr-09-19 05:49PM  
Apr-04-19 09:17AM  
Apr-03-19 09:58AM  
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paul RobertChief Medical OfficerJul 15Sale22.9610,000229,642213,719Jul 17 04:43 PM
MCGUIRE TERRANCEDirectorJun 23Sale31.544,377138,06312,853,817Jun 25 05:53 PM
Polaris Venture Management Co.10% OwnerJun 23Sale31.544,377138,06312,853,817Jun 25 05:47 PM
Paul RobertChief Medical OfficerJun 15Sale29.6110,000296,137223,719Jun 17 04:21 PM
Yu CalvinVice President, FinanceJun 03Sale31.261,34341,981110,686Jun 05 04:40 PM
King RobertChief Development OfficerMay 15Sale27.0015,000404,958477,317May 19 05:23 PM
Paul RobertChief Medical OfficerMay 15Sale27.0010,000270,026233,719May 19 05:23 PM
ORBIMED ADVISORS LLC10% OwnerApr 16Sale23.5362,1831,463,1661,906,718Apr 16 08:23 PM
Paul RobertChief Medical OfficerApr 15Sale22.2710,000222,700243,719Apr 17 05:12 PM
ORBIMED ADVISORS LLC10% OwnerApr 14Sale23.5223,231546,3931,921,804Apr 16 08:23 PM
ORBIMED ADVISORS LLC10% OwnerApr 09Sale23.79288,1016,853,9231,927,440Apr 09 05:30 PM
ORBIMED ADVISORS LLC10% OwnerApr 08Sale23.6582,6141,953,8211,997,333Apr 09 05:30 PM
ORBIMED ADVISORS LLC10% OwnerApr 07Sale23.109,170211,8272,017,374Apr 09 05:30 PM
ORBIMED ADVISORS LLC10% OwnerMar 31Sale24.50250,0006,125,0002,019,598Apr 02 05:06 PM
ORBIMED ADVISORS LLC10% OwnerMar 25Sale24.6656,4111,391,0952,080,243Mar 25 05:54 PM
ORBIMED ADVISORS LLC10% OwnerMar 24Sale24.4567,6441,653,8962,093,927Mar 25 05:54 PM
ORBIMED ADVISORS LLC10% OwnerMar 23Sale26.0514,598380,2782,110,336Mar 25 05:54 PM
Paul RobertChief Medical OfficerMar 13Sale22.9310,000229,286253,719Mar 17 07:07 PM
ORBIMED ADVISORS LLC10% OwnerMar 02Sale26.001,874,20348,729,2780Mar 04 04:17 PM
King RobertChief Development OfficerFeb 14Sale29.5615,000443,376492,317Feb 18 05:00 PM
Paul RobertChief Medical OfficerFeb 14Sale29.5410,000295,390263,719Feb 18 05:00 PM
Yu CalvinVice President, FinanceFeb 07Option Exercise9.5910,22598,088134,719Feb 10 04:42 PM
Oney SabahChief Business OfficerFeb 07Sale35.0319,900697,097573,918Feb 11 05:53 PM
Yu CalvinVice President, FinanceFeb 07Sale35.0224,033841,636110,686Feb 10 04:42 PM
Yu CalvinVice President, FinanceFeb 06Option Exercise8.951,82116,295127,115Feb 10 04:42 PM
Oney SabahChief Business OfficerFeb 06Sale35.001003,500593,818Feb 06 05:48 PM
Yu CalvinVice President, FinanceFeb 06Sale35.002,62191,735124,494Feb 10 04:42 PM
Paul RobertChief Medical OfficerFeb 05Option Exercise8.1610,00081,600283,719Feb 07 08:11 PM
Paul RobertChief Medical OfficerFeb 05Sale32.1010,000321,000273,719Feb 07 08:11 PM
Yu CalvinVice President, FinanceFeb 04Option Exercise8.1613,541110,495188,835Feb 06 05:18 PM
Oney SabahChief Business OfficerFeb 04Option Exercise8.1616,667136,003610,585Feb 06 05:48 PM
Oney SabahChief Business OfficerFeb 04Sale30.0016,667500,010593,918Feb 06 05:48 PM
SCHELLER RICHARD HDirectorFeb 04Sale29.6710,000296,7009,981Feb 06 05:19 PM
Yu CalvinVice President, FinanceFeb 04Sale30.0463,5411,908,772125,294Feb 06 05:18 PM
Wehner David M.DirectorFeb 03Buy25.0020,000500,00044,621Feb 03 06:19 PM
Paul RobertChief Medical OfficerJan 30Option Exercise8.168,00065,280281,719Feb 03 06:14 PM
Paul RobertChief Medical OfficerJan 30Sale28.008,000224,000273,719Feb 03 06:14 PM
Oney SabahChief Business OfficerJan 27Option Exercise8.1614,467118,051608,385Jan 27 05:41 PM
Oney SabahChief Business OfficerJan 27Sale25.0514,467362,398593,918Jan 27 05:41 PM
Paul RobertChief Medical OfficerJan 23Option Exercise8.166,00048,960279,719Jan 27 05:15 PM
Oney SabahChief Business OfficerJan 23Option Exercise8.162,20017,952596,118Jan 27 05:41 PM
Oney SabahChief Business OfficerJan 23Sale25.212,20055,462593,918Jan 27 05:41 PM
Paul RobertChief Medical OfficerJan 23Sale24.326,000145,919273,719Jan 27 05:15 PM
King RobertChief Development OfficerJan 22Sale22.01366507,317Jan 23 04:48 PM
King RobertChief Development OfficerJan 21Sale22.0114,997330,084507,320Jan 23 04:48 PM
Paul RobertChief Medical OfficerJan 15Sale18.6710,000186,700273,719Jan 17 04:53 PM
ORBIMED ADVISORS LLC10% OwnerJan 09Sale19.50379,9977,409,94238,808Jan 13 04:48 PM
ORBIMED ADVISORS LLC10% OwnerDec 26Sale18.6010,800200,88040,200Dec 26 04:54 PM
ORBIMED ADVISORS LLC10% OwnerDec 24Sale19.5971,8001,406,56241,400Dec 26 04:54 PM
ORBIMED ADVISORS LLC10% OwnerDec 23Sale19.8294,2851,868,72949,400Dec 26 04:54 PM
ORBIMED ADVISORS LLC10% OwnerDec 20Sale19.66342,5006,733,55059,800Dec 26 04:54 PM
ORBIMED ADVISORS LLC10% OwnerDec 17Sale18.52954,10017,669,93297,700Dec 19 04:33 PM
Paul RobertChief Medical OfficerDec 13Sale20.0310,000200,300283,719Dec 17 05:33 PM
Oney SabahChief Business OfficerDec 12Option Exercise8.166,81055,570600,728Dec 16 08:13 PM
Oney SabahChief Business OfficerDec 12Sale20.136,810137,069593,918Dec 16 08:13 PM
Oney SabahChief Business OfficerDec 10Option Exercise8.165004,080594,418Dec 12 04:34 PM
Oney SabahChief Business OfficerDec 10Sale20.0150010,005593,918Dec 12 04:34 PM
Oney SabahChief Business OfficerDec 09Option Exercise8.162,30018,768596,218Dec 09 06:36 PM
Oney SabahChief Business OfficerDec 09Sale20.072,30046,161593,918Dec 09 06:36 PM
Oney SabahChief Business OfficerDec 06Option Exercise8.165,15642,073599,074Dec 09 06:36 PM
Oney SabahChief Business OfficerDec 06Sale20.025,156103,223593,918Dec 09 06:36 PM
Oney SabahChief Business OfficerDec 05Option Exercise8.161,50012,240595,418Dec 09 06:36 PM
Oney SabahChief Business OfficerDec 05Sale20.001,50030,000593,918Dec 09 06:36 PM
Yu CalvinVice President, FinanceDec 03Sale18.311,31524,078175,294Dec 05 04:25 PM
KROS Keros Therapeutics, Inc. daily Stock Chart
KROS [NASD]
Keros Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own14.90% Shs Outstand20.18M Perf Week9.37%
Market Cap1.75B Forward P/E- EPS next Y-2.59 Insider Trans5.63% Shs Float18.31M Perf Month20.23%
Income-37.30M PEG- EPS next Q-0.58 Inst Own71.30% Short Float3.44% Perf Quarter43.23%
Sales2.50M P/S700.11 EPS this Y-824.00% Inst Trans4.93% Short Ratio3.93 Perf Half Y157.63%
Book/sh6.48 P/B11.73 EPS next Y37.30% ROA- Target Price59.25 Perf Year-
Cash/sh5.81 P/C13.08 EPS next 5Y- ROE- 52W Range19.10 - 81.00 Perf YTD278.49%
Dividend- P/FCF- EPS past 5Y- ROI73.40% 52W High-6.17% Beta-
Dividend %- Quick Ratio20.00 Sales past 5Y- Gross Margin- 52W Low297.91% ATR6.47
Employees32 Current Ratio20.00 Sales Q/Q- Oper. Margin- RSI (14)76.74 Volatility8.54% 11.46%
OptionableNo Debt/Eq0.00 EPS Q/Q65.10% Profit Margin- Rel Volume0.66 Prev Close75.53
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume160.17K Price76.00
Recom1.50 SMA2023.03% SMA5045.66% SMA20088.91% Volume105,776 Change0.62%
May-04-20Initiated SVB Leerink Outperform $42
May-04-20Initiated Piper Sandler Overweight $35
May-04-20Initiated Jefferies Buy $37
May-04-20Initiated H.C. Wainwright Buy $50
Nov-17-20 04:01PM  
Nov-16-20 08:00AM  
Nov-12-20 10:11PM  
Nov-10-20 05:12PM  
04:17PM  
Nov-09-20 08:00AM  
Nov-04-20 04:01PM  
Oct-27-20 08:35AM  
Oct-20-20 08:00AM  
Sep-14-20 07:01AM  
Sep-11-20 04:01PM  
Aug-13-20 07:00AM  
Aug-10-20 08:00AM  
Aug-04-20 08:00AM  
Jul-29-20 10:12AM  
Jun-26-20 07:01AM  
Jun-24-20 08:34AM  
Jun-12-20 07:01AM  
May-28-20 07:01AM  
May-22-20 07:00AM  
May-14-20 09:15AM  
May-05-20 11:46AM  
Apr-13-20 04:01PM  
Apr-07-20 08:45PM  
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nussbaum RanDirectorNov 17Buy50.0060,0003,000,0002,288,151Nov 19 04:40 PM
Kariv TomerDirectorNov 17Buy50.0060,0003,000,0002,288,151Nov 19 04:39 PM
Pontifax Management 4 G.P. (2010% OwnerNov 17Buy50.0060,0003,000,0002,288,151Nov 19 04:38 PM
IMRA IMARA Inc. daily Stock Chart
IMRA [NASD]
IMARA Inc.
Index- P/E- EPS (ttm)- Insider Own23.05% Shs Outstand17.35M Perf Week41.12%
Market Cap487.20M Forward P/E- EPS next Y-3.84 Insider Trans0.00% Shs Float13.40M Perf Month80.91%
Income- PEG- EPS next Q-0.84 Inst Own64.60% Short Float3.48% Perf Quarter17.89%
Sales- P/S- EPS this Y-107.00% Inst Trans2.48% Short Ratio12.52 Perf Half Y-20.70%
Book/sh5.46 P/B5.31 EPS next Y-0.50% ROA- Target Price41.33 Perf Year-
Cash/sh5.72 P/C5.07 EPS next 5Y- ROE- 52W Range13.40 - 62.71 Perf YTD93.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.76% Beta-
Dividend %- Quick Ratio18.80 Sales past 5Y- Gross Margin- 52W Low116.42% ATR1.94
Employees16 Current Ratio18.80 Sales Q/Q- Oper. Margin- RSI (14)81.88 Volatility13.46% 9.11%
OptionableNo Debt/Eq0.00 EPS Q/Q-23.70% Profit Margin- Rel Volume0.82 Prev Close27.99
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume37.25K Price29.00
Recom1.30 SMA2048.52% SMA5046.25% SMA20025.17% Volume30,537 Change3.61%
Aug-17-20Upgrade Citigroup Neutral → Buy $34 → $30
Jun-30-20Downgrade Citigroup Buy → Neutral $30 → $34
Apr-06-20Initiated SVB Leerink Outperform $25
Apr-06-20Initiated Morgan Stanley Overweight $35
Apr-06-20Initiated Cowen Outperform $25
Nov-17-20 07:00AM  
Nov-05-20 07:00AM  
Oct-31-20 08:00AM  
Oct-29-20 07:00AM  
Oct-16-20 07:00AM  
Sep-02-20 07:00AM  
Aug-25-20 07:00AM  
Aug-14-20 08:26AM  
07:00AM  
Aug-13-20 04:01PM  
Aug-07-20 07:00AM  
Jul-30-20 07:00AM  
Jun-29-20 04:01PM  
Jun-25-20 07:00AM  
Jun-24-20 07:00AM  
Jun-22-20 01:57PM  
Jun-13-20 08:44AM  
Jun-12-20 07:46AM  
07:00AM  
May-21-20 07:00AM  
May-07-20 07:00AM  
May-06-20 07:00AM  
May-04-20 07:00AM  
Apr-23-20 07:00AM  
Mar-11-20 09:57PM  
Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
PASG Passage Bio, Inc. daily Stock Chart
PASG [NASD]
Passage Bio, Inc.
Index- P/E- EPS (ttm)- Insider Own19.38% Shs Outstand45.50M Perf Week18.35%
Market Cap851.55M Forward P/E- EPS next Y-2.94 Insider Trans0.00% Shs Float36.71M Perf Month14.67%
Income- PEG- EPS next Q-0.72 Inst Own79.00% Short Float3.82% Perf Quarter21.97%
Sales- P/S- EPS this Y-257.30% Inst Trans-2.29% Short Ratio7.06 Perf Half Y-10.86%
Book/sh7.45 P/B2.62 EPS next Y-5.00% ROA- Target Price28.50 Perf Year-
Cash/sh7.70 P/C2.54 EPS next 5Y- ROE- 52W Range8.09 - 38.23 Perf YTD-11.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.89% Beta-
Dividend %- Quick Ratio18.30 Sales past 5Y- Gross Margin- 52W Low141.53% ATR0.91
Employees20 Current Ratio18.30 Sales Q/Q- Oper. Margin- RSI (14)77.35 Volatility5.63% 5.13%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.77 Prev Close18.70
ShortableYes LT Debt/Eq0.00 EarningsNov 10 BMO Payout- Avg Volume198.91K Price19.54
Recom2.50 SMA2015.39% SMA5021.51% SMA2004.80% Volume152,689 Change4.49%
Aug-14-20Downgrade JP Morgan Overweight → Neutral $25
Jun-25-20Downgrade Goldman Buy → Neutral $28
Mar-25-20Initiated Chardan Capital Markets Buy $30
Mar-24-20Initiated JP Morgan Overweight $25
Mar-24-20Initiated Goldman Buy $27
Mar-24-20Initiated Cowen Outperform
Nov-24-20 03:55AM  
Nov-23-20 04:01PM  
Nov-11-20 04:30PM  
07:00AM  
Nov-10-20 07:00AM  
Nov-09-20 07:00AM  
Nov-04-20 07:00AM  
Oct-28-20 07:00AM  
Oct-26-20 07:00AM  
Oct-14-20 08:30AM  
Oct-13-20 04:30PM  
Oct-06-20 07:00AM  
Sep-25-20 07:00AM  
Sep-17-20 07:00AM  
Sep-03-20 08:00AM  
Aug-26-20 02:58PM  
Aug-13-20 07:00AM  
Aug-07-20 04:01PM  
Jun-26-20 08:00AM  
Jun-04-20 11:17AM  
08:00AM  
May-28-20 08:35AM  
May-21-20 08:00AM  
May-12-20 05:00PM  
May-11-20 07:00AM  
May-07-20 07:30AM  
May-04-20 08:00AM  
Apr-21-20 08:00AM  
Apr-08-20 08:00AM  
Mar-27-20 08:00AM  
Mar-09-20 04:30PM  
Mar-05-20 08:00AM  
Feb-27-20 07:25PM  
Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
TCDA Tricida, Inc. daily Stock Chart
TCDA [NASD]
Tricida, Inc.
Index- P/E- EPS (ttm)-5.37 Insider Own2.20% Shs Outstand50.12M Perf Week-0.80%
Market Cap377.40M Forward P/E- EPS next Y-3.91 Insider Trans-1.35% Shs Float48.76M Perf Month-9.79%
Income-268.10M PEG- EPS next Q-1.12 Inst Own91.60% Short Float8.98% Perf Quarter-26.72%
Sales- P/S- EPS this Y-53.40% Inst Trans-10.13% Short Ratio3.77 Perf Half Y-71.21%
Book/sh3.21 P/B2.32 EPS next Y26.50% ROA-69.30% Target Price13.00 Perf Year-81.26%
Cash/sh6.29 P/C1.19 EPS next 5Y- ROE-125.60% 52W Range3.74 - 44.30 Perf YTD-80.23%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-83.16% Beta-
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low99.47% ATR0.67
Employees195 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)52.06 Volatility5.84% 11.02%
OptionableYes Debt/Eq1.20 EPS Q/Q-73.60% Profit Margin- Rel Volume0.26 Prev Close7.52
ShortableYes LT Debt/Eq1.11 EarningsNov 09 AMC Payout- Avg Volume1.16M Price7.46
Recom2.70 SMA2012.05% SMA50-9.13% SMA200-61.92% Volume298,698 Change-0.80%
Sep-29-20Resumed JP Morgan Underweight $8
Aug-25-20Downgrade Goldman Buy → Neutral $25 → $10
Jun-27-19Initiated Goldman Buy $48
May-24-19Initiated Needham Buy $50
Jul-23-18Initiated JP Morgan Neutral $34
Jul-23-18Initiated Goldman Neutral $32
Nov-24-20 08:33PM  
Nov-20-20 08:44PM  
Nov-15-20 11:02AM  
Nov-11-20 08:19PM  
Nov-09-20 07:00PM  
04:05PM  
Nov-07-20 09:22PM  
Nov-05-20 08:55PM  
Nov-04-20 08:30PM  
Nov-01-20 10:52AM  
Oct-30-20 08:30PM  
Oct-29-20 06:58PM  
04:35PM  
07:30AM  
Oct-28-20 04:00PM  
Oct-09-20 11:00AM  
Sep-29-20 08:00PM  
08:56AM  
Sep-11-20 02:08PM  
Sep-10-20 12:25PM  
Sep-08-20 02:55PM  
Sep-04-20 05:30PM  
Sep-02-20 12:55PM  
Sep-01-20 11:45PM  
Aug-31-20 08:52PM  
09:12AM  
Aug-29-20 06:27PM  
11:00AM  
Aug-28-20 04:00PM  
12:30PM  
08:00AM  
Aug-27-20 02:45PM  
Aug-26-20 07:23PM  
Aug-24-20 08:30AM  
Aug-05-20 04:05PM  
Jul-29-20 01:00PM  
Jul-17-20 09:52AM  
Jul-16-20 03:15PM  
02:05PM  
10:58AM  
08:31AM  
Jul-15-20 05:00PM  
Jun-15-20 12:24PM  
Jun-03-20 04:39PM  
Jun-02-20 10:00AM  
May-22-20 04:05PM  
May-20-20 12:32AM  
May-19-20 08:13AM  
May-08-20 03:01PM  
May-07-20 04:05PM  
Apr-30-20 10:00AM  
Apr-09-20 11:43AM  
Apr-07-20 08:03PM  
Mar-24-20 08:30AM  
Mar-13-20 01:56PM  
Mar-12-20 09:00AM  
Mar-09-20 08:30AM  
Feb-24-20 04:15PM  
Feb-19-20 10:00AM  
Jan-07-20 01:59PM  
Dec-24-19 11:55AM  
Dec-11-19 02:30PM  
Dec-03-19 08:00AM  
Nov-25-19 10:00AM  
10:00AM  
Nov-14-19 04:08PM  
04:03PM  
Nov-05-19 10:00AM  
Oct-25-19 10:12AM  
Oct-04-19 10:24AM  
Oct-02-19 08:30AM  
Sep-12-19 08:56AM  
Sep-04-19 08:30AM  
Aug-10-19 12:09AM  
Aug-08-19 04:05PM  
Aug-01-19 10:00AM  
Jun-27-19 07:33AM  
07:28AM  
Jun-25-19 09:01PM  
08:30AM  
Jun-18-19 11:10AM  
Jun-17-19 08:32AM  
Jun-05-19 10:00AM  
May-08-19 08:45PM  
04:05PM  
May-03-19 09:25AM  
Apr-30-19 10:13AM  
Apr-23-19 12:29PM  
Apr-08-19 05:03PM  
04:05PM  
Apr-04-19 09:57